Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Eurogentec; NuGen Technologies; Orchid Cellmark

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Eurogentec this week said that its Eurogentec North America subsidiary has received ISO 13485:2003 certification for the production and sale of oligonucleotides for the in vitro diagnostics market. The firm said that it is now the sole custom oligonucleotide contract manufacturing organization to be fully cGMP compliant and have ISO 13485 certified cleanroom sites in North America, Europe, and Asia.

NuGen Technologies has joined the Academy for Medical Development and Collaboration's Vendor Partnership Program, AMDeC announced this week. NuGen's sample preparation products for RNA and DNA analysis will be offered to AMDeC member institutions at a discounted price.

Orchid Cellmark this week said that it has reached an agreement with Accipiter Capital Management, under which Accipiter will nominate two individuals for election to Orchid Cellmark's board of directors. The nominees will serve as Class I directors for three-year terms ending in 2013. Orchid is scheduled to hold its annual shareholders' meeting on Nov. 9.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.